Rinascera Therapeutics Launches With Initial Funding To Advance Treatments For Rare Genetic Skin Diseases

Rinascera Therapeutics, a clinical-stage biotechnology company focused on developing treatments for rare genetic skin diseases, has officially launched after securing its initial financing. The funding round was led by Double Point Ventures, with participation from Olive Tree Capital, Civilization Ventures, and Toba Capital. The company is committed to advancing innovative therapies for rare skin disorders that have well-understood biological causes, significant unmet medical needs, and the potential to improve patients' quality of life. Its pipeline currently includes two clinical-stage programs, RIN-001 and RIN-002, both of which have already demonstrated proof-of-concept results and are expected to move into later-stage clinical development.

The company was incubated by Olive Tree Capital under the leadership of co-founder and Chief Executive Officer Nichola Eliovits. Rinascera was established with the goal of creating transformative treatments for patients living with rare inherited skin disorders. Its name is inspired by the Italian word "rinascere," meaning "to be reborn," reflecting the company's mission to offer patients renewed hope through therapies that target the underlying causes of disease rather than simply managing symptoms.

RIN-001 is a first-in-class topical kinase inhibitor being developed as a cancer interception therapy for people with Gorlin Syndrome and patients who frequently develop sporadic basal cell carcinomas (BCCs). Gorlin Syndrome is a rare inherited condition caused primarily by mutations in the PTCH1 gene, leading to the development of numerous skin cancers throughout a patient's lifetime. Unlike conventional treatment, which often relies on repeated surgeries, RIN-001 is designed to treat early-stage basal cell carcinomas before surgery becomes necessary. Early preclinical and clinical studies have shown encouraging responses, supporting the therapy's potential to provide a less invasive treatment option.

The company's second lead candidate, RIN-002, is an intravenous recombinant collagen VII replacement therapy being developed for Dystrophic Epidermolysis Bullosa (DEB), a rare inherited disease caused by mutations in the COL7A1 gene. The condition results in extremely fragile skin, chronic wounds, severe scarring, and several systemic complications. Unlike therapies that focus only on individual wounds, RIN-002 is designed to replace collagen VII throughout the body, aiming to address both skin-related symptoms and other disease manifestations. The program, which was acquired from BridgeBio, has already generated encouraging preclinical and clinical evidence supporting its therapeutic potential.

According to Nichola Eliovits, patients living with Gorlin Syndrome and DEB need treatments that offer meaningful improvements rather than temporary relief. She said Rinascera was created to develop therapies that target the biological causes of these diseases, helping reduce pain, surgeries, chronic wounds, and long-term complications while improving patients' overall quality of life. The company believes both RIN-001 and RIN-002 have the potential to change the current treatment approach for these rare conditions.

Rinascera aims to build a commercially focused rare disease biotechnology company by developing therapies for diseases with clearly defined biology and high unmet medical need. Dan Yadegar, Managing Partner at Double Point Ventures and a member of the company's Board of Directors, said Rinascera combines experienced leadership with promising clinical-stage programs that have the potential to improve the standard of care for patients. The founding leadership team includes Chief Executive Officer Nichola Eliovits, Chief Operating Officer Max Dawson, and Executive Medical Advisor Karl Beutner, M.D., Ph.D., who believe a strong scientific foundation and patient-focused approach will drive the company's long-term growth in rare dermatology.